A Phase Ia/Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT06585488

Study #:
STUDY00161122

Start Date:
Apr 29, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06585488

View Complete Trial Details & Eligibility at ClinicalTrials.gov